Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Astrocytoma × Eflornithine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Adenomatous Polyposis Coli 2 Urinary Bladder Neoplasms 1 Precancerous Conditions 1 Glioma 1 Colorectal Neoplasms 1 Colonic Polyps 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Temozolomide 16 Radiotherapy 11 Lomustine 8 Carmustine 6 Vincristine 5 Procarbazine 5 Etoposide 3 Corticotropin-Releasing Hormone 3 Carboplatin 3 vorasidenib 2 Thiotepa 2 Radiotherapy, Intensity-Modulated 2 Peripheral Blood Stem Cell Transplantation 2 Methotrexate 2 Isotretinoin 2 Dihematoporphyrin Ether 2 Cisplatin 2 Chemotherapy, Adjuvant 2 etoposide phosphate 1 carmustine, poliferprosan 20 drug combination 1 Valproic Acid 1 Tranexamic Acid 1 Trabedersen 1 Thioguanine 1 Surgical Procedures, Operative 1 Semustine 1 Radiotherapy, Conformal 1 Radiosurgery 1 Prednisone 1 Neoadjuvant Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02796261 2022-01-21

STELLAR

Orbus Therapeutics, Inc.

Phase 3 Unknown

Astrocytoma, Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡